Loading
Life sciences · Journal article
Global South Health Horizons · October 31, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Introduction: Metabolic syndrome (MetS) comprises central obesity, dyslipidaemia, hypertension, and insulin resistance, and carries increased atherothrombotic risk. Soluble P-selectin (sP-selectin), a platelet activation marker, may contribute to vascular complications. This study compared sP-selectin and platelet indices in MetS patients versus controls and examined associations with lipid, atherogenic, and clinical parameters Methods: A cross-sectional study of 100 participants (50 MetS, 50 controls). Fasting venous blood was analysed for sP-selectin, lipid profile, and platelet indices. Analyses included correlation with false discovery rate correction, hierarchical multiple linear regression, trend analysis, and receiver operating characteristic analysis. Results: sP-selectin was higher in MetS than controls (100.0 ± 16.1 vs 58.0 ± 12.1 ng/mL; P < 0.001). MetS participants also had elevated triglycerides, total cholesterol, LDL-C, non-HDL-C, mean platelet volume (MPV), and platelet distribution width, and lower HDL-C. In MetS, sP-selectin correlated positively with atherogenic index of plasma (AIP) and TyG index; both remained significant after FDR correction (q = 0.046). In hierarchical regression, AIP (standardised β = 0.48; P < 0.001), BMI (β = 0.38; P = 0.004), and MPV (β = 0.36; P = 0.004) were independently associated with sP-selectin. sP-selectin increased with MetS component burden and across AIP tertiles. Conclusion: Patients with MetS showed elevated sP-selectin and adverse lipid and platelet profiles. AIP was most consistently associated with sP-selectin; BMI and MPV were independently associated in the final model. These findings suggest sP-selectin may link atherogenic dyslipidaemia to platelet activation in MetS, but longitudinal studies are needed to establish temporal relationships.